We recently sat down with Snowdome Board Director, Helen Buckingham OAM, to get her thoughts on the funding of a new immunotherapy treatment for myeloma, and how clinicians and patients can have their say. Please tell us a bit about yourself My name is Helen Buckingham and I have been involved with Snowdome as a Board Director since its inception in 2010. My background is in politics, and I have...

A state of the art, purpose-built laboratory complex in Victoria will provide new hope to Australian blood cancer patients. Based in Richmond, Melbourne, the...

Snowdome is incredibly proud to continue our international collaboration with the Leukemia & Lymphoma Society in the USA and the Leukaemia Foundation to fund...